ID   MYO5B_HUMAN             Reviewed;        1848 AA.
AC   Q9ULV0; B0I1R3; Q0P656; Q9H6Y6;
DT   27-APR-2001, integrated into UniProtKB/Swiss-Prot.
DT   18-MAY-2010, sequence version 3.
DT   10-MAY-2017, entry version 162.
DE   RecName: Full=Unconventional myosin-Vb;
GN   Name=MYO5B; Synonyms=KIAA1119;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANTS
RP   ALA-126 AND LEU-1055 INS.
RC   TISSUE=Brain;
RX   PubMed=10574461; DOI=10.1093/dnares/6.5.329;
RA   Hirosawa M., Nagase T., Ishikawa K., Kikuno R., Nomura N., Ohara O.;
RT   "Characterization of cDNA clones selected by the GeneMark analysis
RT   from size-fractionated cDNA libraries from human brain.";
RL   DNA Res. 6:329-336(1999).
RN   [2]
RP   SEQUENCE REVISION TO N-TERMINUS AND 918.
RA   Ohara O., Nagase T., Yamakawa H., Kikuno R.;
RL   Submitted (APR-2003) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Colon;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANTS
RP   ALA-126 AND LEU-1055 INS.
RC   TISSUE=Brain;
RA   Yamakawa H., Kikuno R.F., Nagase T., Ohara O.;
RT   "Multiplex amplification and cloning of 5'-ends of cDNA by ligase-free
RT   recombination: preparation of full-length cDNA clones encoding motor
RT   proteins.";
RL   Submitted (JAN-2007) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16177791; DOI=10.1038/nature03983;
RA   Nusbaum C., Zody M.C., Borowsky M.L., Kamal M., Kodira C.D.,
RA   Taylor T.D., Whittaker C.A., Chang J.L., Cuomo C.A., Dewar K.,
RA   FitzGerald M.G., Yang X., Abouelleil A., Allen N.R., Anderson S.,
RA   Bloom T., Bugalter B., Butler J., Cook A., DeCaprio D., Engels R.,
RA   Garber M., Gnirke A., Hafez N., Hall J.L., Norman C.H., Itoh T.,
RA   Jaffe D.B., Kuroki Y., Lehoczky J., Lui A., Macdonald P., Mauceli E.,
RA   Mikkelsen T.S., Naylor J.W., Nicol R., Nguyen C., Noguchi H.,
RA   O'Leary S.B., Piqani B., Smith C.L., Talamas J.A., Topham K.,
RA   Totoki Y., Toyoda A., Wain H.M., Young S.K., Zeng Q., Zimmer A.R.,
RA   Fujiyama A., Hattori M., Birren B.W., Sakaki Y., Lander E.S.;
RT   "DNA sequence and analysis of human chromosome 18.";
RL   Nature 437:551-555(2005).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Colon;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   INTERACTION WITH RAB11FIP2.
RX   PubMed=11495908; DOI=10.1074/jbc.M104831200;
RA   Hales C.M., Griner R., Hobdy-Henderson K.C., Dorn M.C., Hardy D.,
RA   Kumar R., Navarre J., Chan E.K.L., Lapierre L.A., Goldenring J.R.;
RT   "Identification and characterization of a family of Rab11-interacting
RT   proteins.";
RL   J. Biol. Chem. 276:39067-39075(2001).
RN   [8]
RP   IDENTIFICATION IN THE CART COMPLEX.
RX   PubMed=15772161; DOI=10.1091/mbc.E04-11-1014;
RA   Yan Q., Sun W., Kujala P., Lotfi Y., Vida T.A., Bean A.J.;
RT   "CART: an Hrs/actinin-4/BERP/myosin V protein complex required for
RT   efficient receptor recycling.";
RL   Mol. Biol. Cell 16:2470-2482(2005).
RN   [9]
RP   FUNCTION, INTERACTION WITH RAB11A, AND IDENTIFICATION IN A COMPLEX
RP   WITH RAB11A AND CFTR.
RX   PubMed=17462998; DOI=10.1074/jbc.M608531200;
RA   Swiatecka-Urban A., Talebian L., Kanno E., Moreau-Marquis S.,
RA   Coutermarsh B., Hansen K., Karlson K.H., Barnaby R., Cheney R.E.,
RA   Langford G.M., Fukuda M., Stanton B.A.;
RT   "Myosin Vb is required for trafficking of the cystic fibrosis
RT   transmembrane conductance regulator in Rab11a-specific apical
RT   recycling endosomes in polarized human airway epithelial cells.";
RL   J. Biol. Chem. 282:23725-23736(2007).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [11]
RP   FUNCTION, AND INTERACTION WITH NPC1L1.
RX   PubMed=19542231; DOI=10.1074/jbc.M109.034355;
RA   Chu B.-B., Ge L., Xie C., Zhao Y., Miao H.-H., Wang J., Li B.-L.,
RA   Song B.-L.;
RT   "Requirement of myosin Vb.Rab11a.Rab11-FIP2 complex in cholesterol-
RT   regulated translocation of NPC1L1 to the cell surface.";
RL   J. Biol. Chem. 284:22481-22490(2009).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1446, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [13]
RP   FUNCTION, VARIANTS DIAR2 ARG-316; SER-456; ARG-514 AND LEU-660, AND
RP   VARIANT VAL-1688.
RX   PubMed=21206382; DOI=10.1097/MPG.0b013e3181eea177;
RA   Szperl A.M., Golachowska M.R., Bruinenberg M., Prekeris R.,
RA   Thunnissen A.M., Karrenbeld A., Dijkstra G., Hoekstra D., Mercer D.,
RA   Ksiazyk J., Wijmenga C., Wapenaar M.C., Rings E.H.,
RA   van Ijzendoorn S.C.;
RT   "Functional characterization of mutations in the myosin Vb gene
RT   associated with microvillus inclusion disease.";
RL   J. Pediatr. Gastroenterol. Nutr. 52:307-313(2011).
RN   [14]
RP   FUNCTION, INTERACTION WITH RAB11A AND RAB8A, AND MUTAGENESIS OF
RP   GLN-1300; TYR-1307; TYR-1714 AND GLN-1748.
RX   PubMed=21282656; DOI=10.1073/pnas.1010754108;
RA   Roland J.T., Bryant D.M., Datta A., Itzen A., Mostov K.E.,
RA   Goldenring J.R.;
RT   "Rab GTPase-Myo5B complexes control membrane recycling and epithelial
RT   polarization.";
RL   Proc. Natl. Acad. Sci. U.S.A. 108:2789-2794(2011).
RN   [15]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1 (ISOFORM 3), AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [16]
RP   VARIANT DIAR2 LEU-660.
RX   PubMed=19006234; DOI=10.1002/ajmg.a.32605;
RA   Erickson R.P., Larson-Thome K., Valenzuela R.K., Whitaker S.E.,
RA   Shub M.D.;
RT   "Navajo microvillous inclusion disease is due to a mutation in
RT   MYO5B.";
RL   Am. J. Med. Genet. A 146A:3117-3119(2008).
RN   [17]
RP   VARIANTS DIAR2 GLY-108; HIS-219 AND CYS-656.
RX   PubMed=18724368; DOI=10.1038/ng.225;
RA   Mueller T., Hess M.W., Schiefermeier N., Pfaller K., Ebner H.L.,
RA   Heinz-Erian P., Ponstingl H., Partsch J., Roellinghoff B., Koehler H.,
RA   Berger T., Lenhartz H., Schlenck B., Houwen R.J., Taylor C.J.,
RA   Zoller H., Lechner S., Goulet O., Utermann G., Ruemmele F.M.,
RA   Huber L.A., Janecke A.R.;
RT   "MYO5B mutations cause microvillus inclusion disease and disrupt
RT   epithelial cell polarity.";
RL   Nat. Genet. 40:1163-1165(2008).
RN   [18]
RP   VARIANTS DIAR2 GLU-143; ARG-168; HIS-401; ARG-435 AND ARG-1556.
RX   PubMed=20186687; DOI=10.1002/humu.21224;
RA   Ruemmele F.M., Muller T., Schiefermeier N., Ebner H.L., Lechner S.,
RA   Pfaller K., Thoni C.E., Goulet O., Lacaille F., Schmitz J., Colomb V.,
RA   Sauvat F., Revillon Y., Canioni D., Brousse N., de Saint-Basile G.,
RA   Lefebvre J., Heinz-Erian P., Enninger A., Utermann G., Hess M.W.,
RA   Janecke A.R., Huber L.A.;
RT   "Loss-of-function of MYO5B is the main cause of microvillus inclusion
RT   disease: 15 novel mutations and a CaCo-2 RNAi cell model.";
RL   Hum. Mutat. 31:544-551(2010).
RN   [19]
RP   VARIANTS DIAR2 SER-538 AND PHE-550.
RX   PubMed=24138727; DOI=10.1111/tra.12131;
RA   Thoeni C.E., Vogel G.F., Tancevski I., Geley S., Lechner S.,
RA   Pfaller K., Hess M.W., Muller T., Janecke A.R., Avitzur Y., Muise A.,
RA   Cutz E., Huber L.A.;
RT   "Microvillus inclusion disease: loss of Myosin vb disrupts
RT   intracellular traffic and cell polarity.";
RL   Traffic 15:22-42(2014).
RN   [20]
RP   VARIANT DIAR2 LEU-660, AND CHARACTERIZATION OF VARIANT DIAR2 LEU-660.
RX   PubMed=24892806; DOI=10.1172/JCI71651;
RA   Knowles B.C., Roland J.T., Krishnan M., Tyska M.J., Lapierre L.A.,
RA   Dickman P.S., Goldenring J.R., Shub M.D.;
RT   "Myosin Vb uncoupling from RAB8A and RAB11A elicits microvillus
RT   inclusion disease.";
RL   J. Clin. Invest. 124:2947-2962(2014).
CC   -!- FUNCTION: May be involved in vesicular trafficking via its
CC       association with the CART complex. The CART complex is necessary
CC       for efficient transferrin receptor recycling but not for EGFR
CC       degradation. Required in a complex with RAB11A and RAB11FIP2 for
CC       the transport of NPC1L1 to the plasma membrane. Together with
CC       RAB11A participates in CFTR trafficking to the plasma membrane and
CC       TF (transferrin) recycling in nonpolarized cells. Together with
CC       RAB11A and RAB8A participates in epithelial cell polarization.
CC       Together with RAB25 regulates transcytosis.
CC       {ECO:0000269|PubMed:21206382, ECO:0000269|PubMed:21282656}.
CC   -!- SUBUNIT: Component of the CART complex, at least composed of
CC       ACTN4, HGS/HRS, MYO5B and TRIM3. Interacts with RAB11FIP2, RAB11A,
CC       and RAB8A. Found in a complex with CFTR and RAB11A. Interacts with
CC       NPC1L1. {ECO:0000269|PubMed:11495908, ECO:0000269|PubMed:15772161,
CC       ECO:0000269|PubMed:17462998, ECO:0000269|PubMed:19542231,
CC       ECO:0000269|PubMed:21282656}.
CC   -!- INTERACTION:
CC       Q9Y2J4-4:AMOTL2; NbExp=3; IntAct=EBI-311356, EBI-10187270;
CC       Q12982:BNIP2; NbExp=5; IntAct=EBI-311356, EBI-752094;
CC       P15884:TCF4; NbExp=3; IntAct=EBI-311356, EBI-533224;
CC       Q9BYV2:TRIM54; NbExp=3; IntAct=EBI-311356, EBI-2130429;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250|UniProtKB:P70569}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q9ULV0-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9ULV0-2; Sequence=VSP_056199, VSP_056200;
CC         Note=No experimental confirmation available.;
CC       Name=3;
CC         IsoId=Q9ULV0-3; Sequence=VSP_056198;
CC         Note=No experimental confirmation available. Contains a
CC         N-acetylmethionine at position 1. {ECO:0000244|PubMed:22814378};
CC   -!- DISEASE: Diarrhea 2, with microvillus atrophy (DIAR2)
CC       [MIM:251850]: A disease characterized by onset of intractable
CC       life-threatening watery diarrhea during infancy. Two forms are
CC       recognized: early-onset microvillus inclusion disease with
CC       diarrhea beginning in the neonatal period, and late-onset, with
CC       first symptoms appearing after 3 or 4 months of life.
CC       {ECO:0000269|PubMed:18724368, ECO:0000269|PubMed:19006234,
CC       ECO:0000269|PubMed:20186687, ECO:0000269|PubMed:21206382,
CC       ECO:0000269|PubMed:24138727, ECO:0000269|PubMed:24892806}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- SIMILARITY: Belongs to the TRAFAC class myosin-kinesin ATPase
CC       superfamily. Myosin family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA86433.2; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AB032945; BAA86433.2; ALT_INIT; mRNA.
DR   EMBL; AK025336; BAB15114.1; -; mRNA.
DR   EMBL; AB290160; BAG06714.1; -; mRNA.
DR   EMBL; AC090227; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC091044; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC092705; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC105224; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC033527; AAH33527.1; -; mRNA.
DR   CCDS; CCDS42436.1; -. [Q9ULV0-1]
DR   RefSeq; NP_001073936.1; NM_001080467.2. [Q9ULV0-1]
DR   UniGene; Hs.720076; -.
DR   PDB; 4J5M; X-ray; 2.07 A; A=1453-1848.
DR   PDB; 4LNZ; X-ray; 3.11 A; A=1460-1848.
DR   PDB; 4LWZ; X-ray; 2.55 A; B/D=1456-1848.
DR   PDB; 4LX0; X-ray; 2.19 A; B/D=1456-1848.
DR   PDBsum; 4J5M; -.
DR   PDBsum; 4LNZ; -.
DR   PDBsum; 4LWZ; -.
DR   PDBsum; 4LX0; -.
DR   ProteinModelPortal; Q9ULV0; -.
DR   SMR; Q9ULV0; -.
DR   BioGrid; 110729; 48.
DR   IntAct; Q9ULV0; 27.
DR   MINT; MINT-1209283; -.
DR   STRING; 9606.ENSP00000285039; -.
DR   iPTMnet; Q9ULV0; -.
DR   PhosphoSitePlus; Q9ULV0; -.
DR   SwissPalm; Q9ULV0; -.
DR   BioMuta; MYO5B; -.
DR   DMDM; 296439293; -.
DR   EPD; Q9ULV0; -.
DR   PaxDb; Q9ULV0; -.
DR   PeptideAtlas; Q9ULV0; -.
DR   PRIDE; Q9ULV0; -.
DR   Ensembl; ENST00000285039; ENSP00000285039; ENSG00000167306. [Q9ULV0-1]
DR   Ensembl; ENST00000592688; ENSP00000466368; ENSG00000167306. [Q9ULV0-3]
DR   GeneID; 4645; -.
DR   KEGG; hsa:4645; -.
DR   UCSC; uc002ldz.4; human. [Q9ULV0-1]
DR   CTD; 4645; -.
DR   DisGeNET; 4645; -.
DR   GeneCards; MYO5B; -.
DR   H-InvDB; HIX0014446; -.
DR   HGNC; HGNC:7603; MYO5B.
DR   HPA; HPA040593; -.
DR   HPA; HPA040902; -.
DR   HPA; HPA069773; -.
DR   MalaCards; MYO5B; -.
DR   MIM; 251850; phenotype.
DR   MIM; 606540; gene.
DR   neXtProt; NX_Q9ULV0; -.
DR   OpenTargets; ENSG00000167306; -.
DR   Orphanet; 2290; Microvillus inclusion disease.
DR   PharmGKB; PA31408; -.
DR   eggNOG; KOG0160; Eukaryota.
DR   eggNOG; KOG0161; Eukaryota.
DR   eggNOG; COG5022; LUCA.
DR   GeneTree; ENSGT00870000136385; -.
DR   HOGENOM; HOG000152631; -.
DR   HOVERGEN; HBG052556; -.
DR   InParanoid; Q9ULV0; -.
DR   KO; K10357; -.
DR   OMA; YMINAVT; -.
DR   OrthoDB; EOG091G0G93; -.
DR   PhylomeDB; Q9ULV0; -.
DR   TreeFam; TF328771; -.
DR   Reactome; R-HSA-432040; Vasopressin regulates renal water homeostasis via Aquaporins.
DR   ChiTaRS; MYO5B; human.
DR   GeneWiki; MYO5B; -.
DR   GenomeRNAi; 4645; -.
DR   PRO; PR:Q9ULV0; -.
DR   Proteomes; UP000005640; Chromosome 18.
DR   Bgee; ENSG00000167306; -.
DR   CleanEx; HS_MYO5B; -.
DR   ExpressionAtlas; Q9ULV0; baseline and differential.
DR   Genevisible; Q9ULV0; HS.
DR   GO; GO:0045179; C:apical cortex; IDA:UniProtKB.
DR   GO; GO:0030659; C:cytoplasmic vesicle membrane; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0016459; C:myosin complex; IEA:UniProtKB-KW.
DR   GO; GO:0043234; C:protein complex; IDA:UniProtKB.
DR   GO; GO:0003779; F:actin binding; IEA:UniProtKB-KW.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005516; F:calmodulin binding; IEA:UniProtKB-KW.
DR   GO; GO:0000146; F:microfilament motor activity; TAS:Reactome.
DR   GO; GO:0017137; F:Rab GTPase binding; IPI:UniProtKB.
DR   GO; GO:0032439; P:endosome localization; IMP:UniProtKB.
DR   GO; GO:0015031; P:protein transport; IEA:UniProtKB-KW.
DR   GO; GO:0003091; P:renal water homeostasis; TAS:Reactome.
DR   GO; GO:0016192; P:vesicle-mediated transport; IMP:UniProtKB.
DR   InterPro; IPR002710; Dilute_dom.
DR   InterPro; IPR000048; IQ_motif_EF-hand-BS.
DR   InterPro; IPR001609; Myosin_head_motor_dom.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   Pfam; PF01843; DIL; 1.
DR   Pfam; PF00612; IQ; 6.
DR   Pfam; PF00063; Myosin_head; 1.
DR   PRINTS; PR00193; MYOSINHEAVY.
DR   SMART; SM01132; DIL; 1.
DR   SMART; SM00015; IQ; 6.
DR   SMART; SM00242; MYSc; 1.
DR   SUPFAM; SSF52540; SSF52540; 2.
DR   PROSITE; PS51126; DILUTE; 1.
DR   PROSITE; PS50096; IQ; 6.
DR   PROSITE; PS51456; MYOSIN_MOTOR; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Actin-binding; Alternative splicing;
KW   ATP-binding; Calmodulin-binding; Coiled coil; Complete proteome;
KW   Cytoplasm; Disease mutation; Motor protein; Myosin;
KW   Nucleotide-binding; Phosphoprotein; Polymorphism; Protein transport;
KW   Reference proteome; Repeat; Transport.
FT   CHAIN         1   1848       Unconventional myosin-Vb.
FT                                /FTId=PRO_0000123460.
FT   DOMAIN       69    761       Myosin motor.
FT   DOMAIN      769    798       IQ 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00116}.
FT   DOMAIN      792    821       IQ 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00116}.
FT   DOMAIN      817    848       IQ 3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00116}.
FT   DOMAIN      840    869       IQ 4. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00116}.
FT   DOMAIN      865    896       IQ 5. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00116}.
FT   DOMAIN      888    917       IQ 6. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00116}.
FT   DOMAIN     1526   1803       Dilute. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00503}.
FT   NP_BIND     163    170       ATP. {ECO:0000255}.
FT   REGION      640    662       Actin-binding. {ECO:0000255}.
FT   COILED      899   1266       {ECO:0000255}.
FT   COILED     1341   1471       {ECO:0000255}.
FT   COMPBIAS    801    916       Arg-rich.
FT   MOD_RES    1446   1446       Phosphoserine.
FT                                {ECO:0000244|PubMed:20068231}.
FT   VAR_SEQ       1   1430       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_056198.
FT   VAR_SEQ       1    859       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_056199.
FT   VAR_SEQ    1315   1340       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_056200.
FT   VARIANT      10     10       C -> G (in dbSNP:rs16951438).
FT                                /FTId=VAR_056182.
FT   VARIANT     108    108       V -> G (in DIAR2; dbSNP:rs121908103).
FT                                {ECO:0000269|PubMed:18724368}.
FT                                /FTId=VAR_054993.
FT   VARIANT     126    126       T -> A (in dbSNP:rs1815930).
FT                                {ECO:0000269|PubMed:10574461,
FT                                ECO:0000269|Ref.4}.
FT                                /FTId=VAR_063141.
FT   VARIANT     143    143       A -> E (in DIAR2).
FT                                {ECO:0000269|PubMed:20186687}.
FT                                /FTId=VAR_071649.
FT   VARIANT     168    168       G -> R (in DIAR2).
FT                                {ECO:0000269|PubMed:20186687}.
FT                                /FTId=VAR_071650.
FT   VARIANT     219    219       R -> H (in DIAR2).
FT                                {ECO:0000269|PubMed:18724368}.
FT                                /FTId=VAR_054994.
FT   VARIANT     307    307       K -> N (in dbSNP:rs17659179).
FT                                /FTId=VAR_056183.
FT   VARIANT     316    316       G -> R (in DIAR2; dbSNP:rs753558336).
FT                                {ECO:0000269|PubMed:21206382}.
FT                                /FTId=VAR_071651.
FT   VARIANT     401    401       R -> H (in DIAR2).
FT                                {ECO:0000269|PubMed:20186687}.
FT                                /FTId=VAR_071652.
FT   VARIANT     435    435       G -> R (in DIAR2).
FT                                {ECO:0000269|PubMed:20186687}.
FT                                /FTId=VAR_071653.
FT   VARIANT     456    456       N -> S (in DIAR2).
FT                                {ECO:0000269|PubMed:21206382}.
FT                                /FTId=VAR_071654.
FT   VARIANT     514    514       C -> R (in DIAR2).
FT                                {ECO:0000269|PubMed:21206382}.
FT                                /FTId=VAR_071655.
FT   VARIANT     538    538       F -> S (in DIAR2; found in a compound
FT                                heterozygote also carrying F-550;
FT                                enterocytes carrying S-538 and F-550
FT                                display disruption of cell polarity,
FT                                mislocalized apical and basolateral
FT                                transporter proteins and altered
FT                                distribution of endosomal/lysosomal
FT                                constituents including Rab GTPases).
FT                                {ECO:0000269|PubMed:24138727}.
FT                                /FTId=VAR_072814.
FT   VARIANT     550    550       I -> F (in DIAR2; found in a compound
FT                                heterozygote also carrying S-538;
FT                                enterocytes carrying S-538 and F-550
FT                                display disruption of cell polarity,
FT                                mislocalized apical and basolateral
FT                                transporter proteins and altered
FT                                distribution of endosomal/lysosomal
FT                                constituents including Rab GTPases).
FT                                {ECO:0000269|PubMed:24138727}.
FT                                /FTId=VAR_072815.
FT   VARIANT     656    656       R -> C (in DIAR2; dbSNP:rs121908105).
FT                                {ECO:0000269|PubMed:18724368}.
FT                                /FTId=VAR_054995.
FT   VARIANT     660    660       P -> L (in DIAR2; patient enterocytes
FT                                show alterations in junctional
FT                                composition, loss of polarity in
FT                                basolateral and apical compartments, loss
FT                                of apical brush border and formation of
FT                                microvillus inclusions in cells at the
FT                                villus tips; the mutation causes the
FT                                motor to move slowly along F-actin;
FT                                dbSNP:rs121908106).
FT                                {ECO:0000269|PubMed:19006234,
FT                                ECO:0000269|PubMed:21206382,
FT                                ECO:0000269|PubMed:24892806}.
FT                                /FTId=VAR_071656.
FT   VARIANT     918    918       R -> H (in dbSNP:rs2298624).
FT                                /FTId=VAR_056184.
FT   VARIANT     942    942       K -> R (in dbSNP:rs2277716).
FT                                /FTId=VAR_056185.
FT   VARIANT    1055   1055       L -> LL (in dbSNP:rs72530399).
FT                                {ECO:0000269|PubMed:10574461,
FT                                ECO:0000269|Ref.4}.
FT                                /FTId=VAR_063142.
FT   VARIANT    1556   1556       L -> R (in DIAR2).
FT                                {ECO:0000269|PubMed:20186687}.
FT                                /FTId=VAR_071657.
FT   VARIANT    1688   1688       M -> V (in dbSNP:rs112417235).
FT                                {ECO:0000269|PubMed:21206382}.
FT                                /FTId=VAR_071658.
FT   MUTAGEN    1300   1300       Q->L: Abolishes interaction with RAB8A
FT                                and has no effect on RAB11A interaction;
FT                                when associated with C-1307.
FT                                {ECO:0000269|PubMed:21282656}.
FT   MUTAGEN    1307   1307       Y->C: Abolishes interaction with RAB8A
FT                                and has no effect on RAB11A interaction;
FT                                when associated with L-1300.
FT                                {ECO:0000269|PubMed:21282656}.
FT   MUTAGEN    1714   1714       Y->E: Abolishes interaction with RAB11A;
FT                                has no effect on RAB8A interaction.
FT                                {ECO:0000269|PubMed:21282656}.
FT   MUTAGEN    1748   1748       Q->R: Abolishes interaction with RAB11A;
FT                                has no effect on RAB8A interaction.
FT                                {ECO:0000269|PubMed:21282656}.
FT   STRAND     1468   1471       {ECO:0000244|PDB:4J5M}.
FT   HELIX      1474   1476       {ECO:0000244|PDB:4J5M}.
FT   HELIX      1477   1484       {ECO:0000244|PDB:4J5M}.
FT   TURN       1485   1487       {ECO:0000244|PDB:4LX0}.
FT   HELIX      1490   1493       {ECO:0000244|PDB:4J5M}.
FT   HELIX      1500   1514       {ECO:0000244|PDB:4J5M}.
FT   HELIX      1518   1538       {ECO:0000244|PDB:4J5M}.
FT   TURN       1539   1541       {ECO:0000244|PDB:4J5M}.
FT   HELIX      1543   1562       {ECO:0000244|PDB:4J5M}.
FT   HELIX      1567   1569       {ECO:0000244|PDB:4J5M}.
FT   HELIX      1575   1578       {ECO:0000244|PDB:4J5M}.
FT   HELIX      1588   1613       {ECO:0000244|PDB:4J5M}.
FT   HELIX      1614   1616       {ECO:0000244|PDB:4J5M}.
FT   HELIX      1617   1622       {ECO:0000244|PDB:4J5M}.
FT   HELIX      1654   1670       {ECO:0000244|PDB:4J5M}.
FT   HELIX      1675   1699       {ECO:0000244|PDB:4J5M}.
FT   HELIX      1701   1703       {ECO:0000244|PDB:4J5M}.
FT   HELIX      1706   1725       {ECO:0000244|PDB:4J5M}.
FT   HELIX      1729   1731       {ECO:0000244|PDB:4LNZ}.
FT   HELIX      1733   1736       {ECO:0000244|PDB:4J5M}.
FT   HELIX      1738   1746       {ECO:0000244|PDB:4J5M}.
FT   HELIX      1754   1763       {ECO:0000244|PDB:4J5M}.
FT   HELIX      1769   1778       {ECO:0000244|PDB:4J5M}.
FT   HELIX      1791   1800       {ECO:0000244|PDB:4J5M}.
FT   TURN       1801   1803       {ECO:0000244|PDB:4J5M}.
FT   HELIX      1831   1833       {ECO:0000244|PDB:4LX0}.
FT   HELIX      1838   1840       {ECO:0000244|PDB:4J5M}.
FT   STRAND     1845   1848       {ECO:0000244|PDB:4J5M}.
SQ   SEQUENCE   1848 AA;  213672 MW;  4EB8FA02F6B38707 CRC64;
     MSVGELYSQC TRVWIPDPDE VWRSAELTKD YKEGDKSLQL RLEDETILEY PIDVQRNQLP
     FLRNPDILVG ENDLTALSYL HEPAVLHNLK VRFLESNHIY TYCGIVLVAI NPYEQLPIYG
     QDVIYTYSGQ NMGDMDPHIF AVAEEAYKQM ARDEKNQSII VSGESGAGKT VSAKYAMRYF
     ATVGGSASET NIEEKVLASS PIMEAIGNAK TTRNDNSSRF GKYIQIGFDK RYHIIGANMR
     TYLLEKSRVV FQADDERNYH IFYQLCAAAG LPEFKELALT SAEDFFYTSQ GGDTSIEGVD
     DAEDFEKTRQ AFTLLGVKES HQMSIFKIIA SILHLGSVAI QAERDGDSCS ISPQDVYLSN
     FCRLLGVEHS QMEHWLCHRK LVTTSETYVK TMSLQQVINA RNALAKHIYA QLFGWIVEHI
     NKALHTSLKQ HSFIGVLDIY GFETFEVNSF EQFCINYANE KLQQQFNSHV FKLEQEEYMK
     EQIPWTLIDF YDNQPCIDLI EAKLGILDLL DEECKVPKGT DQNWAQKLYD RHSSSQHFQK
     PRMSNTAFII VHFADKVEYL SDGFLEKNRD TVYEEQINIL KASKFPLVAD LFHDDKDPVP
     ATTPGKGSSS KISVRSARPP MKVSNKEHKK TVGHQFRTSL HLLMETLNAT TPHYVRCIKP
     NDEKLPFHFD PKRAVQQLRA CGVLETIRIS AAGYPSRWAY HDFFNRYRVL VKKRELANTD
     KKAICRSVLE NLIKDPDKFQ FGRTKIFFRA GQVAYLEKLR ADKFRTATIM IQKTVRGWLQ
     KVKYHRLKGA TLTLQRYCRG HLARRLAEHL RRIRAAVVLQ KHYRMQRARQ AYQRVRRAAV
     VIQAFTRAMF VRRTYRQVLM EHKATTIQKH VRGWMARRHF QRLRDAAIVI QCAFRMLKAR
     RELKALRIEA RSAEHLKRLN VGMENKVVQL QRKIDEQNKE FKTLSEQLSV TTSTYTMEVE
     RLKKELVHYQ QSPGEDTSLR LQEEVESLRT ELQRAHSERK ILEDAHSREK DELRKRVADL
     EQENALLKDE KEQLNNQILC QSKDEFAQNS VKENLMKKEL EEERSRYQNL VKEYSQLEQR
     YDNLRDEMTI IKQTPGHRRN PSNQSSLESD SNYPSISTSE IGDTEDALQQ VEEIGLEKAA
     MDMTVFLKLQ KRVRELEQER KKLQVQLEKR EQQDSKKVQA EPPQTDIDLD PNADLAYNSL
     KRQELESENK KLKNDLNELR KAVADQATQN NSSHGSPDSY SLLLNQLKLA HEELEVRKEE
     VLILRTQIVS ADQRRLAGRN AEPNINARSS WPNSEKHVDQ EDAIEAYHGV CQTNSKTEDW
     GYLNEDGELG LAYQGLKQVA RLLEAQLQAQ SLEHEEEVEH LKAQLEALKE EMDKQQQTFC
     QTLLLSPEAQ VEFGVQQEIS RLTNENLDLK ELVEKLEKNE RKLKKQLKIY MKKAQDLEAA
     QALAQSERKR HELNRQVTVQ RKEKDFQGML EYHKEDEALL IRNLVTDLKP QMLSGTVPCL
     PAYILYMCIR HADYTNDDLK VHSLLTSTIN GIKKVLKKHN DDFEMTSFWL SNTCRLLHCL
     KQYSGDEGFM TQNTAKQNEH CLKNFDLTEY RQVLSDLSIQ IYQQLIKIAE GVLQPMIVSA
     MLENESIQGL SGVKPTGYRK RSSSMADGDN SYCLEAIIRQ MNAFHTVMCD QGLDPEIILQ
     VFKQLFYMIN AVTLNNLLLR KDVCSWSTGM QLRYNISQLE EWLRGRNLHQ SGAVQTMEPL
     IQAAQLLQLK KKTQEDAEAI CSLCTSLSTQ QIVKILNLYT PLNEFEERVT VAFIRTIQAQ
     LQERNDPQQL LLDAKHMFPV LFPFNPSSLT MDSIHIPACL NLEFLNEV
//
